Trigran Investments Inc. Has $41.73 Million Stock Holdings in MiMedx Group, Inc $MDXG

Trigran Investments Inc. reduced its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 20.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163,384 shares of the company’s stock after selling 1,537,644 shares during the period. MiMedx Group accounts for 8.2% of Trigran Investments Inc.’s portfolio, making the stock its 5th largest position. Trigran Investments Inc. owned approximately 4.16% of MiMedx Group worth $41,726,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. First Light Asset Management LLC raised its stake in MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after buying an additional 1,725,458 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in MiMedx Group by 433.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after purchasing an additional 234,958 shares during the period. Vanguard Group Inc. grew its holdings in MiMedx Group by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after purchasing an additional 382,623 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in MiMedx Group in the fourth quarter worth about $7,134,000. Finally, World Investment Advisors purchased a new stake in MiMedx Group in the fourth quarter worth about $173,000. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $3.60 on Monday. The company’s 50 day moving average price is $3.62 and its 200-day moving average price is $4.91. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.99. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The stock has a market cap of $536.22 million, a price-to-earnings ratio of 18.00 and a beta of 1.48.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The firm had revenue of $58.99 million for the quarter, compared to analysts’ expectations of $65.80 million. On average, equities research analysts forecast that MiMedx Group, Inc will post -0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MDXG has been the topic of a number of recent research reports. Wall Street Zen cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Citizens Jmp cut their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Craig Hallum cut their price objective on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, UBS Group set a $10.00 price objective on shares of MiMedx Group in a report on Monday, February 23rd. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.50.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.